StockNews.AI
ROP
StockNews.AI
148 days

Roper Technologies to acquire CentralReach

1. Roper Technologies announced acquisition of CentralReach for $1.65 billion. 2. CentralReach expected to achieve over 20% organic revenue and EBITDA growth. 3. Transaction will enhance Roper's position in the healthcare software market. 4. CentralReach supports over 200,000 professionals in ABA therapy for ASD. 5. Closing expected by April/May 2025, pending regulatory approval.

10m saved
Insight
Article

FAQ

Why Bullish?

The acquisition aligns with Roper's growth strategy, similar to past successful acquisitions like Verathon. Adding CentralReach enhances ROP's revenue potential in a niche but growing market.

How important is it?

The acquisition represents a significant investment that is expected to drive Roper's future growth and profitability, impacting investor perception positively.

Why Long Term?

Expected consistent revenue growth from CentralReach will provide steady long-term benefits, reminiscent of Roper's past acquisitions boosting revenues sustainably.

Related Companies

VERABATAND
Leading provider of SaaS solutions for Applied Behavior Analysis therapy March 24, 2025 08:30 ET  | Source: Roper Technologies, Inc. SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) today announced that it has reached a definitive agreement to acquire CentralReach from Insight Partners for a net purchase price of approximately $1.65 billion, including a $200 million tax benefit resulting from the transaction. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth. CentralReach is a leading provider of cloud-native software enabling the workflow and administration of Applied Behavior Analysis (“ABA”) therapy. Over 200,000 professionals utilize CentralReach’s purpose-built solutions to help provide care for individuals with autism spectrum disorder (“ASD”) and related intellectual and developmental disabilities (“IDD”). ABA therapy providers rely on CentralReach’s comprehensive electronic medical records platform as their mission critical operating system, which includes highly specialized tools for client set-up, practice management, claims processing, care scheduling, clinical data collection, and service delivery, along with several AI-powered add-on modules. “CentralReach is a fantastic business with clear niche market leadership, mission critical and high ROI solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion,” said Neil Hunn, Roper’s President and CEO. “This acquisition is another example of Roper identifying a business that provides greater value creation for our shareholders. CentralReach meets each of our long-standing acquisition criteria, while also having a structurally faster organic growth profile and the ability to expand margins under Roper’s long-term ownership. We are excited to welcome the CentralReach team to the Roper family and look forward to partnering with the team to execute their strategy.” Acquisition financial outlook and financing CentralReach is expected to contribute approximately $175 million of revenue and $75 million of EBITDA for the twelve months ending June 30, 2026, and will be reported in Roper’s Application Software segment. Roper expects CentralReach to deliver sustainable 20%+ organic revenue and EBITDA growth. The transaction is expected to close in April/May 2025, subject to regulatory approval and customary closing conditions, and will be funded using Roper’s revolving credit facility. Additional information about CentralReach is available in the Investors section of Roper’s website (www.ropertech.com). Use of non-GAAP financial information Roper supplements its consolidated financial statements presented on a GAAP basis with certain non-GAAP financial information, including EBITDA, to provide investors with greater insight, increase transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Roper defines EBITDA as earnings before interest, taxes, depreciation, and amortization. Roper has not provided a reconciliation of the expected EBITDA contribution by CentralReach to the expected net income contribution by CentralReach for the twelve months ending June 30, 2026 because we are unable to quantify certain amounts that would be required to be included in CentralReach’s contribution to net income without unreasonable efforts. In addition, Roper believes such reconciliation would imply a degree of precision that would be confusing or misleading to investors. The non-GAAP financial measure disclosed by Roper in this press release should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP, and the financial results prepared in accordance with GAAP and reconciliations from these results should be carefully evaluated. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com. About CentralReach CentralReach is a leading provider of Autism and IDD Care Software, providing a complete, end-to-end software and services platform that helps therapists who serve children and adults diagnosed with autism spectrum disorder (ASD) and related intellectual and developmental disabilities (IDD). With its roots in Applied Behavior Analysis, the company is revolutionizing how the lifelong journey of autism and IDD care is enabled at home, school, and work with powerful and intuitive solutions purpose-built for each care setting. Trusted by more than 200,000 professionals globally, CentralReach is committed to ongoing product advancement, market-leading industry expertise, world-class client satisfaction, and support of the autism and IDD community to propel autism and IDD care into a new era of excellence. For more information, please visit www.CentralReach.com. Contact information: Investor Relations941-556-2601 investor-relations@ropertech.com The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, acquired businesses, including obtaining any required regulatory approvals with respect thereto. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, including risks related to labor shortages and rising interest rates, changes in foreign exchange rates, risks related to changing U.S. and foreign trade policies, including increased trade restrictions or tariffs, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, including as a result of inflation and potential supply chain constraints, environmental compliance costs and liabilities, risks and cost associated with litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

Related News